Clinical detection of amikacin blood concentration based on surface plasmon resonance (SPR) biosensor

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2300078076

Enrollment

Unknown

Registered

2023-11-28

Start date

2023-12-01

Completion date

Unknown

Last updated

2023-12-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infection

Interventions

Infection group (high-performance liquid chromatography, SPR):None

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Admission to ICU, aged 18 years or older 2. Application of Amikacin 3.Voluntary signing of informed consent form

Exclusion criteria

Exclusion criteria: Patients with various reasons that affect blood drug concentration detection

Design outcomes

Primary

Measure	Time frame
Amikacin drug concentration;Amikacin drug concentration;Amikacin drug concentration;Amikacin drug concentration;	—

Countries

China

Contacts

Public ContactYanfei Mao, Rongrong Ren

Xinhua Hospital, Shanghai Jiaotong University School of Medicine

maoyanfei@xinhuamed.com.cn+86 21 2507 7825

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026